Actavis exec leaps to CEO job at rival Impax; Glaxo COPD med nabs Canadian approval; Jury slaps doc with $14M in damages in Yasmin case;

@FiercePharma: Top-read story over the long weekend: Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says. Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: Bill that would have paid drug disposal costs in California out of pharma's pocket left in the recycle bin. Article | Follow @EricPFierce

@CarlyHFierce: Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay. More | Follow @CarlyHFierce

> Actavis ($ACT) said its president of global R&D, G. Frederick Wilkinson, will leave the company to take the helm of generics rival Impax Laboratories ($IPXL). Release

> GlaxoSmithKline's ($GSK) chronic obstructive pulmonary disease treatment Incruse Ellipta won approval in Canada. Release

> A Chicago jury awarded $14 million to a woman who sued her doctor over a stroke she suffered after taking Bayer's birth control pill Yasmin. Report

> Merck Serono's new president and CEO, Belén Garijo, has been appointed as an independent director of L'Oréal. Report

> Drug side-effects data company AdverseEvents closed a $2 million Series A funding round, aiming to expand its sales force and analyst teams, and step up marketing efforts. Release

> Cubist Pharma pulled one lot of its antibiotic Cubicin after a customer reported glass particles in a vial from that lot. Report

Medical Device News

@FierceMedDev: OPKO Health to buy Israeli inhaler developer Inspiro Medical for undisclosed price. News | Follow @FierceMedDev

@VarunSaxena2: Report: Pfizer pitches $101B megamerger to struggling AstraZeneca - FierceBiotech. More from FierceBiotech | Follow @VarunSaxena2

@EmilyWFierce: Wearable data glove that translates motion into sound could mean big things for the American deaf community. Story | Follow @EmilyWFierce

@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic, Edwards need heart-to-heart over post-injunction access. More

> EndoStim bags a CE mark for MRI-safe reflux device. Item

> Advanced Cardiac Therapeutics raises $7M-plus for ablation catheter technology. Story

Biotech News

@FierceBiotech: Former Creighton professor named chief medical officer at 23andMe. Roundup | Follow @FierceBiotech

@JohnCFierce: I added the top 5 rounds from Q1 in my biotech VC story. And not a one of the biotechs is in the Boston area. Story | Follow @JohnCFierce

@DamianFierce: Here's some NYTimes background on the procedure FDA's warning about (with a remarkably NYTish headline): Article (sub. req.)| Follow @DamianFierce

@EmilyMFierce: New MRSA superbug emerges in Brazilian patient. Story | Follow @EmilyMFierce

> Sarepta rockets up after mapping a shortcut to the FDA with DMD hopeful eteplirsen. Story

> Zafgen tees up an $86M IPO for eye-catching obesity drug. More

> Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate. News

CRO News

> Certara buys Synchrogenix with its eye on regulatory writing. Story

> InVentiv signs up to get IntelliCell's regenerative drug into the clinic. More

> AMRI plans to shutter an R&D shop to save cash. Article

> Quintiles taps OmniComm for early-stage data management. News

> WuXi poaches an AstraZeneca exec to amp up Chinese R&D. Report

Biotech IT News

> U.K. and Canadian governments back bioinformatics, omics research projects. More

> BlackBerry plans healthcare-focused smartphone after making eClinical investment. Story

> Europe puts data management at the heart of $4B drug innovation drive. Article

> Pfizer, PhRMA and others pick holes in FDA social media guidance. News

> Google adds UCSF geneticist to Calico's roster. Report

And Finally... Some generic drugs have had eye-popping price spikes. Report

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.